Amicus Therapeutics Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
511
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$5.77B
Amicus Therapeutics General Information
Description
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Contact Information
Website
www.amicusrx.comCorporate Office
- 47 Hulfish Street
- Princeton, NJ 08542
- United States
Corporate Office
- 47 Hulfish Street
- Princeton, NJ 08542
- United States
Amicus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 17. Merger/Acquisition | 27-Apr-2026 | $5.77B | Completed | Generating Revenue | ||
| 16. Debt Refinancing | 02-Oct-2023 | Completed | Generating Revenue | |||
| 15. PIPE | 29-Sep-2021 | Completed | Generating Revenue | |||
| 14. 2PO | 31-May-2019 | Completed | Generating Revenue | |||
| 13. Debt - Acquisition | 01-Sep-2018 | Completed | Generating Revenue | |||
| 12. 2PO | 16-Feb-2018 | Completed | Generating Revenue | |||
| 11. 2PO | 11-Jun-2015 | Completed | Generating Revenue | |||
| 10. PIPE | 03-Dec-2013 | Completed | Generating Revenue | |||
| 9. PIPE | 20-Nov-2013 | $3M | $290M | Completed | Generating Revenue | |
| 8. PIPE | 30-Jul-2012 | $18.6M | $287M | Completed | Generating Revenue |
Amicus Therapeutics Comparisons
Industry
Financing
Details
Amicus Therapeutics Competitors (49)
One of Amicus Therapeutics’s 49 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Avidity Biosciences | Formerly VC-backed | San Diego, CA | ||||
| Idorsia Pharmaceuticals | Corporation | Allschwil, Switzerland | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Xenon Pharmaceuticals | Formerly VC-backed | Burnaby, Canada |
Amicus Therapeutics Patents
Amicus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260076951-A1 | Methods of treating fabry disease in patients having renal impairment | Pending | 19-Sep-2024 | ||
| WO-2026006625-A1 | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease | Pending | 26-Jun-2024 | ||
| WO-2026006625-A9 | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease | Pending | 26-Jun-2024 | ||
| WO-2025264978-A2 | Recombinant alpha-galactosidase a proteins and gene therapy | Pending | 20-Jun-2024 | ||
| WO-2025264978-A3 | Recombinant alpha-galactosidase a proteins and gene therapy | Pending | 20-Jun-2024 | C12Y302/01022 |
Amicus Therapeutics Signals
Amicus Therapeutics Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BlackRock | Asset Manager | Minority | ||
| CHL Medical Partners | Venture Capital | Minority | ||
| Canaan Partners | Venture Capital | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| GSK | Corporation | Minority |
Amicus Therapeutics Acquisitions (4)
Amicus Therapeutics’s most recent deal was a Merger/Acquisition with Celenex for . The deal was made on 20-Sep-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Celenex | 20-Sep-2018 | Merger/Acquisition | Buildings and Property | ||
| MiaMed | 05-Jul-2016 | Merger/Acquisition | Buildings and Property | ||
| Scioderm | 30-Sep-2015 | Merger/Acquisition | Pharmaceuticals | ||
| Callidus Biopharma | 21-Nov-2013 | Merger/Acquisition | Drug Delivery |
Amicus Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
23.58 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Amicus Therapeutics Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Amicus Therapeutics Canada | Toronto, Canada | 2017 | |
| Amicus Biologics | Philadelphia, PA | 2002 |
Amicus Therapeutics FAQs
-
When was Amicus Therapeutics founded?
Amicus Therapeutics was founded in 2002.
-
Where is Amicus Therapeutics headquartered?
Amicus Therapeutics is headquartered in Princeton, NJ.
-
What is the size of Amicus Therapeutics?
Amicus Therapeutics has 511 total employees.
-
What industry is Amicus Therapeutics in?
Amicus Therapeutics’s primary industry is Drug Discovery.
-
Is Amicus Therapeutics a private or public company?
Amicus Therapeutics is a Private company.
-
What is the current valuation of Amicus Therapeutics?
The current valuation of Amicus Therapeutics is .
-
What is Amicus Therapeutics’s current revenue?
The current revenue for Amicus Therapeutics is .
-
How much funding has Amicus Therapeutics raised over time?
Amicus Therapeutics has raised $1.28B.
-
Who are Amicus Therapeutics’s investors?
BlackRock, CHL Medical Partners, Canaan Partners, Frazier Healthcare Partners, and GSK are 5 of 17 investors who have invested in Amicus Therapeutics.
-
Who are Amicus Therapeutics’s competitors?
Avidity Biosciences, Idorsia Pharmaceuticals, Sangamo Therapeutics, Capricor Therapeutics, and Xenon Pharmaceuticals are some of the 49 competitors of Amicus Therapeutics.
-
When was Amicus Therapeutics acquired?
Amicus Therapeutics was acquired on 27-Apr-2026.
-
Who acquired Amicus Therapeutics?
Amicus Therapeutics was acquired by BioMarin Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process